Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 324

1.

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.

Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators.

Lancet. 2010 Mar 6;375(9717):807-15. doi: 10.1016/S0140-6736(09)62125-5.

PMID:
20206776
[PubMed - indexed for MEDLINE]
2.

Apixaban or enoxaparin for thromboprophylaxis after knee replacement.

Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ.

N Engl J Med. 2009 Aug 6;361(6):594-604. doi: 10.1056/NEJMoa0810773. Erratum in: N Engl J Med. 2009 Oct 29;361(18):1814.

PMID:
19657123
[PubMed - indexed for MEDLINE]
Free Article
3.

Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.

Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT, Lassen MR.

J Bone Joint Surg Br. 2012 Feb;94(2):257-64. doi: 10.1302/0301-620X.94B2.27850.

PMID:
22323697
[PubMed - indexed for MEDLINE]
4.

The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.

Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D.

J Thromb Haemost. 2007 Dec;5(12):2368-75. Epub 2007 Sep 15.

PMID:
17868430
[PubMed - indexed for MEDLINE]
5.

Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.

Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI; ADOPT Trial Investigators.

N Engl J Med. 2011 Dec 8;365(23):2167-77. doi: 10.1056/NEJMoa1110899. Epub 2011 Nov 13.

PMID:
22077144
[PubMed - indexed for MEDLINE]
Free Article
6.

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S; RECORD2 Investigators.

Lancet. 2008 Jul 5;372(9632):31-9. doi: 10.1016/S0140-6736(08)60880-6. Epub 2008 Jun 24.

PMID:
18582928
[PubMed - indexed for MEDLINE]
7.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.

Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; RECORD4 Investigators.

Lancet. 2009 May 16;373(9676):1673-80. doi: 10.1016/S0140-6736(09)60734-0. Epub 2009 May 4.

PMID:
19411100
[PubMed - indexed for MEDLINE]
8.

Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials.

Huang J, Cao Y, Liao C, Wu L, Gao F.

Thromb Haemost. 2011 Feb;105(2):245-53. doi: 10.1160/TH10-08-0552. Epub 2010 Oct 12.

PMID:
20941455
[PubMed - indexed for MEDLINE]
9.

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group.

N Engl J Med. 2008 Jun 26;358(26):2765-75. doi: 10.1056/NEJMoa0800374.

PMID:
18579811
[PubMed - indexed for MEDLINE]
Free Article
10.

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.

Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators.

N Engl J Med. 2010 Dec 23;363(26):2487-98. doi: 10.1056/NEJMoa1006885.

PMID:
21175312
[PubMed - indexed for MEDLINE]
Free Article
11.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators.

N Engl J Med. 2008 Jun 26;358(26):2776-86. doi: 10.1056/NEJMoa076016.

PMID:
18579812
[PubMed - indexed for MEDLINE]
Free Article
12.

Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.

Lassen MR, Bauer KA, Eriksson BI, Turpie AG; European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee.

Lancet. 2002 May 18;359(9319):1715-20.

PMID:
12049858
[PubMed - indexed for MEDLINE]
13.

Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery.

Deeks ED.

Drugs. 2012 Jun 18;72(9):1271-91. doi: 10.2165/11209020-000000000-00000. Review.

PMID:
22686618
[PubMed - indexed for MEDLINE]
14.

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.

Bauer KA, Eriksson BI, Lassen MR, Turpie AG; Steering Committee of the Pentasaccharide in Major Knee Surgery Study.

N Engl J Med. 2001 Nov 1;345(18):1305-10.

PMID:
11794149
[PubMed - indexed for MEDLINE]
Free Article
15.

BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.

Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kälebo P, Misselwitz F, Gent M; OdiXa-Knee Study Group.

J Thromb Haemost. 2005 Nov;3(11):2479-86.

PMID:
16241946
[PubMed - indexed for MEDLINE]
16.

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.

Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ; RE-NOVATE II Study Group.

Thromb Haemost. 2011 Apr;105(4):721-9. doi: 10.1160/TH10-10-0679. Epub 2011 Jan 12.

PMID:
21225098
[PubMed - indexed for MEDLINE]
17.

Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin.

Fuji T, Ochi T, Niwa S, Fujita S.

J Orthop Sci. 2008 Sep;13(5):442-51. doi: 10.1007/s00776-008-1264-0. Epub 2008 Oct 9.

PMID:
18843459
[PubMed - indexed for MEDLINE]
18.

Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.

Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, Eskilson C, Nylander I, Frison L, Ogren M; METHRO III Study Group.

Thromb Haemost. 2003 Feb;89(2):288-96.

PMID:
12574809
[PubMed - indexed for MEDLINE]
19.

A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.

Weitz JI, Cao C, Eriksson BI, Fisher W, Kupfer S, Raskob G, Spaeder J, Turpie AG.

Thromb Haemost. 2010 Dec;104(6):1150-7. doi: 10.1160/TH10-05-0273. Epub 2010 Sep 30.

PMID:
20886185
[PubMed - indexed for MEDLINE]
20.

Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.

Turpie AG, Bauer KA, Eriksson BI, Lassen MR; PENTATHALON 2000 Study Steering Committee.

Lancet. 2002 May 18;359(9319):1721-6. Erratum in: Lancet 2002 Oct 5;360(9339):1102.

PMID:
12049860
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk